Psoralen from Sigma-Aldrich
CleanBox DNA Workstation from Bio-Rad
Mouse Anti-Human VRK2 Monoclonal Antibody, Unconjugated, Clone 3B10 from Abnova Corporation
Mouse Anti-Human PPIL2 Monoclonal Antibody, Unconjugated, Clone 2E11 from Abnova Corporation
Biology Products:(Date:11/4/2009)... , RIDGE, N.Y., Oct. 21 What,... to preventing accidental death resulting from pre...Parents with good intentions, however, may be unaw...protecting their teens from the ticking timebomb o...ional leader in premium-quality medical supplies, ...
(Date:11/4/2009)... , NEW YORK, Oct. 27 Global R...company and advanced R&D laboratory, today ann...ode and is prepared to actively commercialize its ...-edge biometric security offerings. ,, During t...millions of dollars to develop and deploy a series...
(Date:11/4/2009)... , SEATTLE, Nov. 4 Glencoe So...scopy Environment (OME) Consortium ( http://openm...ration with the American Society of Cell Biology,s...ibrary." The ASCB has been awarded a $2.5M stimulu...s (NIH) Grand Opportunities program, as part of th...
Breaking Biology News(10 mins):MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3Glencoe Software to Support the ASCB 'Stimulus Grant' to Build Virtual Image Library of the Cell 2Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 2 Study of MM 111 a Bispecific Antibody to ErbB2 3 50725 1Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 2 Study of MM 111 a Bispecific Antibody to ErbB2 3 50725 2Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 2 Study of MM 111 a Bispecific Antibody to ErbB2 3 50725 3Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 2 Study of MM 111 a Bispecific Antibody to ErbB2 3 50725 4McCaughey Urges Use of First NYS Hospital Infection Report 4681 1Bad medicine 50722 1(Date:11/5/2009)...Nov. 5 Transgenomic, Inc...cial results for the quarter ended September 30, 2... in the tables that follow. ,, Third Quarter 2...,000 or $0.01 per share for the third quarter of 2... per share for the third quarter of 2008. ,, N...
(Date:11/5/2009)...f., Nov. 5 WaferGen Bios... developer of state-of-the-art genetic analysis sy...D. has joined the company,s Scientific Advisory Bo... commercializing novel molecular diagnostics for c... development of computational biology systems for ...
(Date:11/5/2009)... Brooke Sanders brings a new look to Pro Rep...ovember 5, 2009 -- Professional Reprographics, Ora...ompany is pleased to present Brooke Sanders to the...cs/PR specialist. The addition of Brooke to the co...ithin Professional Reprographics., , ,Brooke bring...
(Date:11/4/2009)...KVILLE, Md., Nov. 4 Zyngenia, Inc.... on next-generation antibody drug development, tod...ries A funding from New Enterprise Associates (NEA...s. The capital will be used to create novel, multi... or more biological targets with a single agent. T...
Breaking Biology Technology:Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4Zyngenia, Inc. Raises $10 Million in Series A Funding 2Zyngenia, Inc. Raises $10 Million in Series A Funding 3Zyngenia, Inc. Raises $10 Million in Series A Funding 4